Lactocepin as a protective microbial structure in the context of IBD

Gut Microbes

Volumn 4, Issue 2, 2013, Pages 152-157

  Hörmannsperger, Gabriele ^a   von Schillde, Marie Anne ^a   Haller, Dirk ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

CEP; Chemokines; IBD; Inflammation; Lactocepin; Probiotic; Protease; prtP

Indexed keywords

BACTERIAL PROTEIN; CD4 ANTIGEN; INTERLEUKIN 10; LACTOCEPIN; POLYSACCHARIDE; PROTEIN P40; UNCLASSIFIED DRUG; VSL3;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ENTERITIS; HUMAN; INFLAMMATION; LACTOBACILLUS CASEI; LACTOBACILLUS PARACASEI; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PSORIASIS; SKIN ALLERGY;

CEP; CHEMOKINES; IBD; INFLAMMATION; LACTOCEPIN; PROBIOTIC; PROTEASE; PRTP;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; LACTOBACILLUS CASEI; MODELS, BIOLOGICAL; PROBIOTICS; SERINE ENDOPEPTIDASES;

EID: 84874786762     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.23444     Document Type: Article

References (37)

1. Sanders ME, Akkermans LM, Haller D, Hammerman C, Heimbach J, Hörmannsperger G, et al. Safety assessment of probiotics for human use. Gut Microbes 2010; 1:164-185; PMID:21327023; http://dx.doi.org/10.4161/gmic.1.3.12127.
2. Lebeer S, Vanderleyden J, De Keersmaecker SC. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 2010; 8:171-184; PMID:20157338; http://dx.doi.org/10.1038/nrmicro2297.
3. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004; 126:1358-1373; PMID:15131797; http://dx.doi.org/10.1053/j.gastro.2004.02.003.
4. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A 2007; 104:7617-7621; PMID:17456596; http://dx.doi.org/10.1073/pnas.0700440104.
5. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011; 469:543-547; PMID:21270894; http://dx.doi.org/10.1038/nature09646.
6. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008; 453:620-625; PMID:18509436; http://dx.doi.org/10.1038/nature07008.
7. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 2010; 107:12204-12209; PMID:20566854; http://dx.doi.org/10.1073/pnas.0909122107.
8. Shen Y, Torchia ML, Lawson GW, Karp CL, Ashwell JD, Mazmanian SK. Outer membrane vesicles of a human commensal mediate immune regulation and disease protection. Cell Host Microbe 2012; 12:509-520; PMID:22999859; http://dx.doi.org/10.1016/j.chom.2012.08.004.
9. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 2002; 277:50959-50965; PMID:12393915; http://dx.doi.org/10.1074/jbc.M207050200.
10. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007; 132:562-575; PMID:17258729; http://dx.doi.org/10.1053/j.gastro.2006.11.022.
11. Yan F, Cao H, Cover TL, Washington MK, Shi Y, Liu L, et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest 2011; 121:2242-2253; PMID:21606592; http://dx.doi.org/10.1172/JCI44031.
12. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010; CD001176; PMID:20556748.
13. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7:1202-1209, 1209, e1; PMID:19631292; http://dx.doi.org/10.1016/j.cgh.2009.07.016.
14. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105:221827; PMID:20517305; http://dx.doi.org/10.1038/ajg.2010.218.
15. Hoermannsperger G, Clavel T, Hoffmann M, Reiff C, Kelly D, Loh G, et al. Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation. PLoS One 2009; 4:e4365; PMID:19197385; http://dx.doi.org/10.1371/journal.pone.0004365.
16. Ostvik AE, Vb Granlund A, Bugge M, Nilsen NJ, Torp SH, Waldum HL, et al. Enhanced expression of CXCL10 in inflammatory bowel disease: Potential role of mucosal toll-like receptor 3 stimulation. Inflamm Bowel Dis 2012; In press; PMID:22685032.
17. Schroepf S, Kappler R, Brand S, Prell C, Lohse P, Glas J, et al. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis 2010; 16:1882-1890; PMID:20848514; http://dx.doi.org/10.1002/ibd.21312.
18. Sasaki S, Yoneyama H, Suzuki K, Suriki H, Aiba T, Watanabe S, et al. Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur J Immunol 2002; 32:3197-3205; PMID:12555665; http://dx.doi.org/10.1002/1521-4141(200211)32:113197::AIDIMMU31973.0.CO; 2-1.
19. Hyun JG, Lee G, Brown JB, Grimm GR, Tang Y, Mittal N, et al. Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm Bowel Dis 2005; 11:799-805; PMID:16116313; http://dx.doi.org/10.1097/01.MIB.0000178263.34099.89.
20. Singh UP, Singh S, Singh R, Cong Y, Taub DD, Lillard JW Jr. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res 2008; 28:3143; PMID:18370870; http://dx.doi.org/10.1089/jir.2007.0059.
21. von Schillde MA, Hörmannsperger G, Weiher M, Alpert CA, Hahne H, Bäuerl C, et al. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell Host Microbe 2012; 11:387-396; PMID:22520466; http://dx.doi.org/10.1016/j.chom.2012.02.006.
22. Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2010; 3:49-56; PMID:19794409; http://dx.doi.org/10.1038/mi.2009.116.
23. Treuting PM, Dintzis SM. Lower gastrointestinal tract, In: Comparative Anatomy and Histology: A Mouse and Human Atlas. London: Academic Press, 2012.
24. Van Huynegem K, Steidler L. Clinical development of lactocepin: a novel bacterial biologic? Expert Rev Clin Immunol 2012; 8:597-599; PMID:23078055; http://dx.doi.org/10.1586/eci.12.55.
25. Siezen RJ. Multi-domain, cell-envelope proteinases of lactic acid bacteria. Antonie Van Leeuwenhoek 1999; 76:139-155; PMID:10532376; http://dx.doi.org/10.1023/A:1002036906922.
26. Sadat-Mekmene L, Genay M, Atlan D, Lortal S, Gagnaire V. Original features of cell-envelope proteinases of Lactobacillus helveticus. A review. Int J Food Microbiol 2011; 146:1-13; PMID:21354644; http://dx.doi.org/10.1016/j.ijfoodmicro.2011.01.039.
27. Broadbent JR, Barnes M, Brennand C, Strickland M, Houck K, Johnson ME, et al. Contribution of Lactococcus lactis cell envelope proteinase specificity to peptide accumulation and bitterness in reduced-fat Cheddar cheese. Appl Environ Microbiol 2002; 68:1778-1785; PMID:11916696; http://dx.doi.org/10.1128/AEM.68.4.1778-1785.2002.
28. Marugg JD, van Kranenburg R, Laverman P, Rutten GA, de Vos WM. Identical transcriptional control of the divergently transcribed prtP and prtM genes that are required for proteinase production in lactococcus lactis SK11. J Bacteriol 1996; 178:1525-1531; PMID:8626277.
29. Nikolic M, Tolinacki M, Fira D, Golic N, Topisirovic L. Variation in specificity of the PrtP extracellular proteinases in Lactococcus lactis and Lactobacillus paracasei subsp. paracasei. Folia Microbiol (Praha) 2009; 54:188-194; PMID:19649733; http://dx.doi.org/10.1007/s12223-009-0029-2.
30. Ahrné S, Lönnermark E, Wold AE, Aberg N, Hesselmar B, Saalman R, et al. Lactobacilli in the intestinal microbiota of Swedish infants. Microbes Infect 2005; 7:1256-1262; PMID:16002310; http://dx.doi.org/10.1016/j.micinf.2005.04.011.
31. Štšepetova J, Sepp E, Kolk H, Lõivukene K, Songisepp E, Mikelsaar M. Diversity and metabolic impact of intestinal Lactobacillus species in healthy adults and the elderly. Br J Nutr 2011; 105:1235-1244; PMID:21303568; http://dx.doi.org/10.1017/S0007114510004770.
32. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al.; MetaHIT Consortium. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464:59-65; PMID:20203603; http://dx.doi.org/10.1038/nature08821.
33. Lee EY, Lee ZH, Song Y W. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun Rev 2012; PMID:23092582; http://dx.doi.org/10.1016/j.autrev.2012.10.001.
34. Flier J, Boorsma DM, van Beek PJ, Nieboer C, Stoof TJ, Willemze R, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001; 194:398-405; PMID:11523046; http://dx.doi.org/10.1002/1096-9896(200108)194:4397::AIDPATH8993.0.CO;2- S.
35. Chen SC, de Groot M, Kinsley D, Laverty M, McClanahan T, Arreaza M, et al. Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res 2010; 302:113-123; PMID:19517126; http://dx.doi.org/10.1007/s00403-009-0966-2.
36. Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009; 1173:310-317; PMID:19758167; http://dx.doi.org/10.1111/j.1749-6632.2009.04813.x.
37. Lee EY, Lee ZH, Song Y W. CXCL10 and autoimmune diseases. Autoimmun Rev 2009; 8:379-383; PMID:19105984; http://dx.doi.org/10.1016/j.autrev.2008.12.002.